Preparation of tumor-specific magnetoliposomes and their application for hyperthermia

被引:66
|
作者
Le, B
Shinkai, M
Kitade, T
Honda, H
Yoshida, J
Wakabayashi, T
Kobayashi, T [1 ]
机构
[1] Nagoya Univ, Grad Sch Engn, Dept Biotechnol, Nagoya, Aichi 4648603, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi 4668550, Japan
关键词
hyperthermia therapy; magnetic particle; drug delivery; antibody; immobilization;
D O I
10.1252/jcej.34.66
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
Magnetoliposomes (MLs) were conjugated with an antibody fragment to give specificity to a tumor. The antibody fragment was cross-linked to N-(6-maleimidocaproyloxy)-dipalmitoyl phosphatidylethanolamine (EMC-DPPE) in tiposomal membrane. The immobilization of the antibody fragment was optimal when the content of EMC-DPPE was 10-wt% and the reaction time for immobilization was 18 h. The Fab' fragment-conjugating hits (FMLs) were 2.4 times higher molar immobilization density compared with the method using the whole antibody. The targetability of the FMLs to the glioma cells, U251-SP, was then investigated. The amount of FMLs uptake reached 85 pg/cell in an in vitro experiment using plastic dishes. In an in vivo experiment using glioma-harboring mice, 260 mug of the FMLs per 1 g of tumor tissue accumulated (tumor sizes was 0.1 cm(3)), which corresponded to approximately 60% of the total injection. This value was 7 times higher than that of the MLs. After injection of the FMLs, mice were exposed to intracellular hyperthermia using the alternating magnetic field irradiation. The temperature of tumor tissue increased to 43 degreesC and the growth of the tumor was found to be arrested over 2 weeks. These results indicate the FMLs could target the glioma cells in vitro and in vivo, and are efficiently applicable to the hyperthermia of tumor.
引用
收藏
页码:66 / 72
页数:7
相关论文
共 50 条
  • [21] Tumor-specific apoptosis by Apoptin®
    Noteborn, MHM
    GENE THERAPY, 1999, 6 : S10 - S10
  • [22] TUMOR-SPECIFIC TRANSPLANTATION ANTIGENS
    KLEIN, E
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1969, 164 (A2) : 344 - &
  • [23] UNIQUE TUMOR-SPECIFIC ANTIGENS
    SCHREIBER, H
    WARD, PL
    ROWLEY, DA
    STAUSS, HJ
    ANNUAL REVIEW OF IMMUNOLOGY, 1988, 6 : 465 - 483
  • [24] TUMOR-SPECIFIC IMMUNE MECHANISMS
    SMITH, RT
    NEW ENGLAND JOURNAL OF MEDICINE, 1968, 278 (23): : 1268 - &
  • [25] Tumor-specific adenoviral vectors
    Deisseroth, A
    CANCER GENE THERAPY, 1999, 6 (06) : S17 - S17
  • [26] CHARACTERISTICS OF TUMOR-SPECIFIC ANTIGENS
    LAW, LW
    CANCER SURVEYS, 1985, 4 (01) : 3 - 19
  • [27] Tumor local chemohyperthermia using docetaxel-embedded magnetoliposomes: Interaction of chemotherapy and hyperthermia
    Yoshida, Motohira
    Sato, Mitsunori
    Yamamoto, Yuji
    Maehara, Tsunehiro
    Naohara, Takashi
    Aono, Hiromichi
    Sugishita, Hiroki
    Sato, Koichi
    Watanabe, Yuji
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (02) : 406 - 411
  • [28] A tumor-specific stem cell
    Ciara Metcalfe
    Frederic J de Sauvage
    Nature Genetics, 2013, 45 : 7 - 9
  • [29] WHAT ARE TUMOR-SPECIFIC ANTIGENS
    DAVIES, AL
    NATURE, 1975, 254 (5502) : 653 - 654
  • [30] OVARIAN TUMOR-SPECIFIC ANTIGENS
    KNAUF, S
    URBACH, GI
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1974, 119 (07) : 966 - 970